Prior to taking up senior positions with the pharmaceutical company
GlaxoSmithKline (GSK) and later in the UK Government, Vallance spent several years in medical research.[7]
St George's Hospital
From 1986 to 1995 he taught at St George's Hospital Medical School,[2][6] where his research concentrated on
vascular biology and
endothelial cell physiology.[8][9] Prior to the discovery of the involvement of
nitric oxide, it was believed that
high blood pressure was usually a result of constrictor activity in blood vessels. Vallance performed studies which demonstrated the link between nitric oxide and blood pressure.[10]
In 1987, with
Joe Collier, he set out to investigate whether human blood vessels demonstrated endothelium-dependent relaxation, a term coined in 1980 by
Robert F. Furchgott and John V. Zawadzki after discovering that a
large blood vessel would not relax when its
single-layered inner most lining was removed. Furchgott and Zawadzki subsequently showed that the occurrence was mediated by what they called
endothelium-derived relaxing factor, later found to be nitric oxide, and it was shortly shown to occur in a variety of animals. Using veins from the back of a human hand, Vallance and Collier reproduced Furchgott and Zawadzki's findings.[1][11] Subsequently, their team showed that the human
arterial vasculature is actively dilated by a continuous release of nitric oxide.[9][12] In 1991, Vallance and
Salvador Moncada published a paper on the role of nitric oxide in
cirrhosis, proposing an association between the changes in blood flow in cirrhosis and the vasoactive properties of nitric oxide.[13] The following year they reported that the plasma concentrations of
asymmetric dimethylarginine (ADMA) were elevated in people who were
uraemic.[14][15]
University College Hospital
From 1995 to 2002 he was a professor at
UCL Medical School, then Professor of Medicine from 2002 to 2006, and head of medicine.[2][16] He was also
registrar of the
Academy of Medical Sciences.[9] In 2005, as head of the division of medicine at UCL, he published a paper in the Journal of the Royal Society of Medicine, titled "A post-take ward round", in which he suggested that "reinvention of teams of doctors, nurses, therapists and social workers seems like an important task for general medicine".[17][18][19]
GlaxoSmithKline
In 2006, in his mid-40s, he joined GSK as head of
drug discovery.[20][21] Four years later he became head of medicines discovery and development, and in 2012 he was appointed head of research and development at GSK.[22][23][24][25][26] Under his leadership, new medicines for
cancer,
asthma,
autoimmune diseases and
HIV infection were discovered and approved for use worldwide. He championed
open innovation and novel industry-academic partnerships globally,[9][27][25] and maintained a focus on the search for new
antibiotics and treatments for
tropical diseases.[9][28]
UK Government
In March 2018, Vallance left GSK, and on 4 April 2018 he began his five-year tenure as
Chief Scientific Adviser to the UK Government, replacing the interim officeholder
Chris Whitty.[29] In this role he led the
Government Office for Science, advising the prime minister and the cabinet.[30][31] In 2018, he was one of nine scientific advisers who, in a paper in Nature, called for "inclusive, rigorous, transparent, and accessible information for policy makers" and supported the Evidence-Based Research Network, established in 2016, to "lobby for all proposals for new research to be supported by references to systematic reviews of relevant existing research".[32]
In September, it emerged that Vallance owns a deferred bonus of 43,111 shares worth £600,000 in GlaxoSmithKline, a company which is working on developing a COVID vaccine.[36] This led to claims of a potential conflict of interest, as Vallance could be seen to have a financial interest in pushing for a vaccine-based response to the pandemic whether or not this is objectively the best approach.[37] Then Health Secretary
Matt Hancock denied that this was the case, with a government spokesperson stating that, "Upon his appointment, appropriate steps were taken to manage the Government Chief Scientific Adviser's interests in line with advice provided at the time. The GCSA has no input into contractual and commercial decisions on vaccine procurement which are taken by Ministers following a robust cross-Government approvals regime".[38]
After a televised briefing alongside Johnson and Whitty on 31 October, where a second "lockdown" was introduced for England, Vallance was criticised for showing two slides – projecting hospital admissions and deaths – which were later reissued with worst-case figures revised downward.[39][40][41] Five days later, a statement from the
Office for Statistics Regulation called for greater transparency in published data relating to the pandemic, including publication of data sources and modelling assumptions; the statement did not refer to any specific presentation but was linked by reporters to the 31 October briefing.[42][43]
^
ab"Career profile; Patrick Vallance". St George's Alumni Newsletter; The magazine for Alumni and friends of St George’s, University of London. Issue 16 (spring 2013), p.18-19.
^Barba, Gianvincenzo; Mullen, Michael J.; Donald, Anne; MacAllister, Raymond J. (1999). "Determinants of the Response of Human Blood Vessels to Nitric Oxide Donors In Vivo". Journal of Pharmacology and Experimental Therapeutics. 289 (3): 1662–1668.
ISSN0022-3565.
PMID10336566.